Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026)

Spero Therapeutics (SPRO) has reported Other Non Operating Income for 11 consecutive years, with -$3000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income fell 175.0% year-over-year to -$3000.0; the trailing twelve-month figure through Jun 2026 stood at -$2000.0 (down 102.56% YoY), and the FY2025 full-year result was $7000.0, down 88.33% from the prior year.
• Other Non Operating Income fell to -$3000.0 in Q2 2026 per SPRO's latest filing, from -$1000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $995000.0 in Q2 2022 and bottomed at -$193000.0 in Q1 2022.
• Historically, Other Non Operating Income has averaged $56764.7 across 5 years, with a median of -$1000.0 in 2026.
• The widest YoY moves for Other Non Operating Income: up 3200.0% in 2024, down 600.0% in 2024.
• Over 5 years, Other Non Operating Income stood at $141000.0 in 2022, then plunged by 97.87% to $3000.0 in 2023, then surged by 3200.0% to $99000.0 in 2024, then slumped by 97.98% to $2000.0 in 2025, then sank by 250.0% to -$3000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$3000.0, -$1000.0, and $2000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.